{"protocolSection":{"identificationModule":{"nctId":"NCT02678455","orgStudyIdInfo":{"id":"PR-15097"},"secondaryIdInfos":[{"id":"Dengue TV005 in Dhaka","type":"OTHER","domain":"NIAID"}],"organization":{"fullName":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"},"briefTitle":"Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh","officialTitle":"Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh"},"statusModule":{"statusVerifiedDate":"2024-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-03"},"primaryCompletionDateStruct":{"date":"2017-08-10","type":"ACTUAL"},"completionDateStruct":{"date":"2020-02-05","type":"ACTUAL"},"studyFirstSubmitDate":"2016-02-05","studyFirstSubmitQcDate":"2016-02-05","studyFirstPostDateStruct":{"date":"2016-02-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2024-02-20","resultsFirstSubmitQcDate":"2025-01-16","resultsFirstPostDateStruct":{"date":"2025-01-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-01-16","lastUpdatePostDateStruct":{"date":"2025-01-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"},"collaborators":[{"name":"University of Vermont","class":"OTHER"},{"name":"Johns Hopkins Bloomberg School of Public Health","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka, Bangladesh.","detailedDescription":"Dengue viruses (DENV) are the leading arboviral infection globally, with over 2 billion people at risk of infection worldwide. The first dengue fever outbreak in Bangladesh occurred in 2000, and since then, dengue fever has had a continued presence throughout Bangladesh. This study will evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka, Bangladesh.\n\nThe study will enroll four cohorts of participants: adults, adolescents, children, and young children. Study researchers will evaluate study data for each cohort before enrolling the subsequent cohort.\n\nParticipants will be randomly assigned to receive either TV005 vaccine or placebo at study entry (Day 0). Additional study visits will occur on Days 7, 14, 28, 56, 180, 360, 720, and 1080. Study visits will include blood collection, physical examinations, and clinical assessments. Participants will record and monitor their temperature and symptoms until Day 14. Study staff will contact participants daily until Day 14; after Day 14, study staff will contact participants weekly (and after Day 180, monthly) throughout the study for follow-up health monitoring."},"conditionsModule":{"conditions":["Dengue"],"keywords":["Dengue Virus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":192,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"TV005 vaccine","type":"EXPERIMENTAL","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).","interventionNames":["Biological: TV005 vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive one dose of placebo at study entry (Day 0).","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"TV005 vaccine","description":"Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30.","armGroupLabels":["TV005 vaccine"],"otherNames":["TetraVax-DV T005"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Delivered by subcutaneous injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Study Participants With Each Solicited, Related Adverse Event Types of Any Severity.","description":"Collected through daily home visits up to day 14, clinic visits for physical exam and hematological and blood chemistry labs, and weekly phone surveillance after day 14. Study staff record temperatures and AEs on the surveillance source document.","timeFrame":"Vaccine/placebo administration (study day 0) up to 28 days post vaccine/placebo administration"},{"measure":"Percentage of Study Participants Who Are Seropositive Following Vaccination","description":"Measured by serum plaque reduction neutralization titer, 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses at study day 14, 28, 58, and 180 post vaccination. Seropositivity to each serotype as defined as PRNT50\\>=10.\n\nPer protocol analysis includes participants meeting eligibility criteria, complying with defined visits and protocols, no elimination criteria, and immunogenicity data endpoints measures available.","timeFrame":"Study day 14 through study day 180"}],"secondaryOutcomes":[{"measure":"Proportion of Study Participants With Vaccine Virus Recovered Following Vaccination","description":"Viremia in serum was determined both by amplification and direct titration using Vero cell monolayers. Each specific serotype was identified using monoclonal antibodies.","timeFrame":"Vaccine administration (study day 0) up to 14 days post vaccine administration"},{"measure":"Percentage of Seropositive Study Participants Among Dengue Experienced and Dengue Naive Vaccinees.","description":"Measured by serum plaque reduction neutralization titer, 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses at study day 14, 28, 56, and 180 post vaccination. Seropositivity to each serotype is defined as PRNT50 ≥ 10.","timeFrame":"Study day 14 through study day 180"},{"measure":"Durability of Seropositivity Post TV005 Vaccination","description":"Estimated percent seropositive, over 3 years by age group and serotype. Measured by serum plaque reduction neutralization titer, 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses at study day 14, 28, 56, 180, 360, 720, and 1080 post vaccination. Seropositivity to each serotype is defined as PRNT50 ≥ 10.","timeFrame":"Vaccine/placebo administration (study day 0) up to three years post vaccine/placebo administration (study day 1080)."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy males or females (non-pregnant or lactating) between the ages of 12 months and 50 years at the time of enrollment into the study.\n* Reside in Mirpur Wards 2, 3, or 5 (or other Wards within Mirpur as designated by the PI if needed to reach enrollment targets) at the time of screening.\n* Study participants and/or their parents/guardians/legally acceptable or authorized representatives (LARs) who the Investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visits).\n* Good general health as determined by physical examination, laboratory screening, and review of medical history.\n* If the participant is greater than or equal to 18 years of age, an informed consent form signed and dated by the study participant (and by an independent witness if required by local regulations). If the study participant is a minor, an assent form (for participants age 11-17 years) and informed consent form signed and dated by the participant's properly identified parent(s) or legally acceptable representative. If a participant is less than 11 years of age, the participant's parent(s) or legally acceptable representative will consent by signing the consent form for minor participants.\n* If the participant is female, she must not be pregnant or planning to become pregnant up to 28 days post vaccination. Female participants under the age of 18 will be enrolled, if they have not yet reached menarche. Females 18 years of age or older, must be properly using a method of pregnancy prevention that is known to be highly effective per the PI. Reliable methods of contraception include: hormonal birth control, condoms with spermicide, diaphragm with spermicide, surgical sterilization, intrauterine device, and abstinence (greater than or equal to 6 months since last sexual encounter). For female study participants who are 18 years of age or older pregnancy testing will occur at screening and again before vaccination and they must have a negative pregnancy test prior to vaccination. Additionally, they will receive counselling on the importance of effective contraception during the 30 days prior to vaccination and continuing up to Day 28. Counselling will occur at their screening visit, on all clinic visit days up to Day 28. Female participants 18 years of age and older will be subject to pregnancy testing on the Study Day 28 and 56 visits. If female participants under the age of 18 that have not yet reached menarche prior to enrollment, reach menarche during the study, they will continue to be enrolled and followed-up through the entire three year follow-up period.\n\nExclusion Criteria:\n\n* Pregnant or lactating female or female planning to become pregnant within 28 days of receiving an investigational product or planning to discontinue abstinence or contraceptive precautions within 28 days of receiving an investigational product. Menstruating females under the age of 18 will be excluded from being enrolled.\n* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, autoimmune, hematologic, or endocrine disease or functional defect, as determined by history, physical examination, or screening tests.\n* History of any neurological, psychiatric, or behavioural disorder or seizures, with the exception of a single febrile seizure in childhood.\n* Self-reported or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent, greater than or equal to 0.5 mg/kg/day or 20 mg/day, for more than 2 consecutive weeks within the past 3 months). Inhaled and topical steroids are allowed.\n* Having a height-for-age z-score (HAZ) or weight-for-age z-score (WAZ) of less than or equal to 3 for children under the age of two. Severe malnutrition as observed by the study physician for all study participants ages 2 years old and older.\n* Hepatitis C virus (HCV) infection by screening and confirmatory assays (screening in adults and adolescents only), or hepatitis B virus (HBV) infection, by hepatitis B surface antigen (HBsAg) screening (all participants) or, unwilling to allow HCV (adults and adolescents only) and HBV testing.\n* Screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), alanine transaminase (ALT), or platelet count, as defined in this protocol.\n* For children under 5 years of age, screening laboratory values of Grade 1 or above for Haemoglobin.\n* History of allergic reaction likely to be exacerbated by any component of the vaccine; any history of a severe allergic reaction or anaphylaxis.\n* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures.\n* Any other condition that in the opinion of the Investigator would jeopardize the safety or rights of a participant participating in the trial or would render the participant unable to comply with the protocol.\n* Planned administration of any vaccine from 30 days prior to receipt of the study vaccine and ending 30 days after; with the exceptions of standard infant and child Expanded Program on Immunization (EPI) inactivated vaccines and the inactivated influenza vaccine or the inactivated rabies vaccine (without administration of immunoglobulin) administered to adults or children.\n* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding receipt of study vaccine/placebo or planned use at any time during the study period or history of having received any investigational dengue vaccine at any previous time.\n* Current participation in any clinical or investigational study.\n* Administration of immunoglobulins and/or blood products within 90 days preceding the dose or planned administration at any time during the study period, which might interfere with assessment of the immune response.\n* A planned or anticipated move to a location that will prohibit full participation in the trial for the three year duration.\n* Potential adult volunteers or parents of potential child volunteers, who do not have easy access to a fixed or mobile telephone.\n* Any participant that resides in a household with an individual previously enrolled in an older age cohort in this study. Only one participant from each household will be enrolled.\n* Any participant identified as a site employee of the Investigator or study clinic, with direct involvement in the proposed study or other studies under the direction of that Investigator or study clinic, as well as any immediate family member (such as husband, wife and their children, adopted or natural) of the clinic employees or the Investigator.\n\nElimination Criteria During the Study:\n\nThe following criteria should be checked at each visit subsequent to the first visit. If any become applicable during the study, it will not require withdrawal of the participant from the study but may determine a participant's evaluability in the per-protocol (PP) analysis. The participant will continue to be evaluated for safety purposes at the regularly scheduled visits. See the protocol for definition of study cohorts to be evaluated.\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine/placebo during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed.\n* Administration of a licensed vaccine during the period starting from 30 days before dose of vaccine/placebo and ending 30 days after, with the exception of standard infant and childhood EPI \"inactivated\" vaccinations.\n* Administration of immunoglobulins and/or any blood products during the study period.\n* Pregnancy within the 28 days after investigational product administration.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"50 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Rashidul Haque, MD","affiliation":"Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Beth D. Kirkpatrick, MD","affiliation":"Vaccine Testing Center, University of Vermont College of Medicine","role":"STUDY_CHAIR"}],"locations":[{"facility":"International Centre for Diarrhoeal Disease Research, Bangladesh","city":"Mīrpur","state":"Dhaka Division","country":"Bangladesh","geoPoint":{"lat":23.99511,"lon":90.32359}}]},"referencesModule":{"references":[{"pmid":"16474082","type":"BACKGROUND","citation":"Podder G, Breiman RF, Azim T, Thu HM, Velathanthiri N, Mai le Q, Lowry K, Aaskov JG. Origin of dengue type 3 viruses associated with the dengue outbreak in Dhaka, Bangladesh, in 2000 and 2001. Am J Trop Med Hyg. 2006 Feb;74(2):263-5."},{"pmid":"25801652","type":"BACKGROUND","citation":"Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22."},{"pmid":"37776876","type":"DERIVED","citation":"Walsh MR, Alam MS, Pierce KK, Carmolli M, Alam M, Dickson DM, Bak DM, Afreen S, Nazib F, Golam K, Qadri F, Diehl SA, Durbin AP, Whitehead SS, Haque R, Kirkpatrick BD. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. Lancet Infect Dis. 2024 Feb;24(2):150-160. doi: 10.1016/S1473-3099(23)00520-0. Epub 2023 Sep 27."}],"seeAlsoLinks":[{"label":"International Center for Diarrhoeal Diseases Research, Bangladesh","url":"http://www.icddrb.org/"}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."},{"id":"FG001","title":"Placebo","description":"Participants will receive one dose of placebo at study entry (Day 0).\n\nPlacebo: Delivered by subcutaneous injection"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"48"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"135"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Two participants met protocol specified elimination criteria from the non-safety analyses. Analysis of baseline characteristics and Adverse Events are completed on 144 vaccine and 48 placebo recipients. The two participants that met protocol specified elimination criteria were on the vaccine arm and therefore only 142 vaccine and 48 placebo recipients were included in the analyses of proportion seropositive and proportion with recovered vaccine virus and or wild type virus after vaccination","groups":[{"id":"BG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."},{"id":"BG001","title":"Placebo","description":"Participants will receive one dose of placebo at study entry (Day 0).\n\nPlacebo: Delivered by subcutaneous injection"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"measures":[{"title":"Age, Customized","populationDescription":"Row population differs from overall because they are subgroups of the overall population. For each of the four subgroups (Adult, Adolescent, Children, and Young children), there are 36 study participants in the TV005 vaccine arm and 12 study participants in the Placebo arm, with a total of 144 in the TV005 vaccine arm and 48 in the Placebo arm.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"title":"Adult","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"32.17","spread":"8.26"},{"groupId":"BG001","value":"29.25","spread":"5.10"},{"groupId":"BG002","value":"31.44","spread":"8.24"}]}]},{"title":"Adolescent","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"12.58","spread":"1.81"},{"groupId":"BG001","value":"12.83","spread":"1.64"},{"groupId":"BG002","value":"12.65","spread":"1.75"}]}]},{"title":"Children","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"8.14","spread":"1.46"},{"groupId":"BG001","value":"7.83","spread":"1.34"},{"groupId":"BG002","value":"8.06","spread":"1.42"}]}]},{"title":"Young Children","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"3.25","spread":"0.81"},{"groupId":"BG001","value":"3.42","spread":"0.52"},{"groupId":"BG002","value":"3.29","spread":"0.74"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Adult Female","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"28"}]}]},{"title":"Adult Male","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"20"}]}]},{"title":"Adolescent Female","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"21"}]}]},{"title":"Adolescent Male","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"27"}]}]},{"title":"Child Female","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"33"}]}]},{"title":"Child Male","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"15"}]}]},{"title":"Young Child Female","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"19"}]}]},{"title":"Young Child Male","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"29"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Bangladesh","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}]}]},{"title":"Dengue Serostatus","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Dengue Naive","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"103"}]}]},{"title":"Dengue Experienced","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"89"}]}]}]},{"title":"Age Cohort","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Adult group (18-50 years)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}]},{"title":"Adolescent group (11-17 years)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}]},{"title":"Children group (5-10 years)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}]},{"title":"Young children group (1-4 years)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"192"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"48"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Study Participants With Each Solicited, Related Adverse Event Types of Any Severity.","description":"Collected through daily home visits up to day 14, clinic visits for physical exam and hematological and blood chemistry labs, and weekly phone surveillance after day 14. Study staff record temperatures and AEs on the surveillance source document.","populationDescription":"Per Protocol: all participants who received study vaccine/placebo according to random assignment according to dose are in analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Vaccine/placebo administration (study day 0) up to 28 days post vaccine/placebo administration","groups":[{"id":"OG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."},{"id":"OG001","title":"Placebo","description":"Participants will receive one dose of placebo at study entry (Day 0).\n\nPlacebo: Delivered by subcutaneous injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"Erythema","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"ALT Increased","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Hemoglobin Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Leukocytosis","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"PTT Prolonged","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Thrombocytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"7"}]}]},{"title":"Rash","categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"6"}]}]},{"title":"Arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}]},{"title":"Photophobia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Retro-orbital Pain","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Decrease in Activity","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Loss of Appetite","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Erythema","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.216","ciUpperLimit":"0.141","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Swelling","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.216","ciUpperLimit":"0.141","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"ALT Increased","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.135","ciUpperLimit":"0.119","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Hemoglobin Decreased","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.135","ciUpperLimit":"0.119","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Leukocytosis","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.020","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.205","ciUpperLimit":"0.121","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"PTT Prolonged","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.024","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.127","ciUpperLimit":"0.111","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Thrombocytopenia","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.056","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.022","ciUpperLimit":"0.134","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Fever","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.051","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.018","ciUpperLimit":"0.118","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Headache","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"-0.036","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.203","ciUpperLimit":"0.089","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Rash","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.166","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.016","ciUpperLimit":"0.275","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Arthralgia","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.063","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.030","ciUpperLimit":"0.126","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Fatigue","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.023","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.155","ciUpperLimit":"0.118","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Myalgia","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.041","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.105","ciUpperLimit":"0.105","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Nausea","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.019","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.160","ciUpperLimit":"0.114","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Photophobia","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.216","ciUpperLimit":"0.141","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Retro-orbital Pain","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.024","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.142","ciUpperLimit":"0.088","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Decrease in Activity","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.216","ciUpperLimit":"0.141","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Loss of Appetite","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.028","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.216","ciUpperLimit":"0.141","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."},{"groupIds":["OG000","OG001"],"groupDescription":"Vomiting","nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"0.083","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.165","ciUpperLimit":"0.218","estimateComment":"Adjusted proportion difference (TV005 minus Placebo) with inverse variance weighting and Newcombe Score confidence intervals."}]},{"type":"PRIMARY","title":"Percentage of Study Participants Who Are Seropositive Following Vaccination","description":"Measured by serum plaque reduction neutralization titer, 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses at study day 14, 28, 58, and 180 post vaccination. Seropositivity to each serotype as defined as PRNT50\\>=10.\n\nPer protocol analysis includes participants meeting eligibility criteria, complying with defined visits and protocols, no elimination criteria, and immunogenicity data endpoints measures available.","populationDescription":"Only TV005 Vaccine arm included in analysis as per protocol to determine percentage of participants in TV005 vaccine arm who are seropositive after vaccination. Data is analyzed for each sub-group. Two participants (one each in Adult and Adolescent vaccine group) were eliminated from this analysis. There are 35 participants in Adult and Adolescent vaccine Arm groups; 36 in Children, and Young Children vaccine Arm groups with a total of 142 included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Study day 14 through study day 180","groups":[{"id":"OG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"classes":[{"title":"All study participants seropositive to DENV-1 post TV005 Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"76","upperLimit":"88"}]}]},{"title":"All study participants seropositive to DENV-2 post TV005 Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"96","upperLimit":"100"}]}]},{"title":"All study participants seropositive to DENV-3 post TV005 Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"92","upperLimit":"98"}]}]},{"title":"All study participants seropositive to DENV-4 post TV005 Vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87","lowerLimit":"81","upperLimit":"92"}]}]},{"title":"Adult study participants seropositive to DENV-1 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Adult study participants seropositive to DENV-2 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adult study participants seropositive to DENV-3 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adult study participants seropositive to DENV-4 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Adolescent study participants seropositive to DENV-1 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"67","upperLimit":"92"}]}]},{"title":"Adolescent study participants seropositive to DENV-2 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90","upperLimit":"100"}]}]},{"title":"Adolescent study participants seropositive to DENV-3 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adolescent study participants seropositive to DENV-4 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Children study participants seropositive to DENV-1 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81","lowerLimit":"65","upperLimit":"90"}]}]},{"title":"Children study participants seropositive to DENV-2 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90","upperLimit":"100"}]}]},{"title":"Children study participants seropositive to DENV-3 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90","upperLimit":"100"}]}]},{"title":"Children study participants seropositive to DENV-4 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78","lowerLimit":"62","upperLimit":"88"}]}]},{"title":"Young children study participants seropositive to DENV-1 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"68","upperLimit":"92"}]}]},{"title":"Young children study participants seropositive to DENV-2 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90","upperLimit":"100"}]}]},{"title":"Young children study participants seropositive to DENV-3 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Young children study participants seropositive to DENV-4 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"82","upperLimit":"98"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"All study participants seropositive to DENV-1 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"76","ciUpperLimit":"88"},{"groupIds":["OG000"],"groupDescription":"All study participants seropositive to DENV-2 post TV005 Vaccination. There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"96","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"All study participants seropositive to DENV-3 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm","paramType":"percentage seropositive","paramValue":"96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"92","ciUpperLimit":"98"},{"groupIds":["OG000"],"groupDescription":"All study participants seropositive to DENV-4 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"81","ciUpperLimit":"92"},{"groupIds":["OG000"],"groupDescription":"Adult study participants seropositive to DENV-1 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"Adult study participants seropositive to DENV-2 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adult study participants seropositive to DENV-3 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adult study participants seropositive to DENV-4 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Adolescent study participants seropositive to DENV-1 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"67","ciUpperLimit":"92"},{"groupIds":["OG000"],"groupDescription":"Adolescent study participants seropositive to DENV-2 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"90","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"Adolescent study participants seropositive to DENV-3 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adolescent study participants seropositive to DENV-4 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"Children study participants seropositive to DENV-1 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"65","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"Children study participants seropositive to DENV-2 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"90","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"Children study participants seropositive to DENV-3 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"90","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"Children study participants seropositive to DENV-4 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62","ciUpperLimit":"88"},{"groupIds":["OG000"],"groupDescription":"Young Children study participants seropositive to DENV-1 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68","ciUpperLimit":"92"},{"groupIds":["OG000"],"groupDescription":"Young Children study participants seropositive to DENV-2 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"90","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"Young Children study participants seropositive to DENV-3 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Young Children study participants seropositive to DENV-4 post TV005 Vaccination There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"82","ciUpperLimit":"98"}]},{"type":"SECONDARY","title":"Proportion of Study Participants With Vaccine Virus Recovered Following Vaccination","description":"Viremia in serum was determined both by amplification and direct titration using Vero cell monolayers. Each specific serotype was identified using monoclonal antibodies.","populationDescription":"Per protocol analysis includes all study participants meeting all eligibility criteria and with viremia data endpoints measures available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Vaccine administration (study day 0) up to 14 days post vaccine administration","groups":[{"id":"OG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."},{"id":"OG001","title":"Placebo","description":"Participants will receive one dose of placebo at study entry (Day 0).\n\nPlacebo: Delivered by subcutaneous injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"48"}]}],"classes":[{"title":"DENV-1 recovered","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"DENV-2 recovered","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"DENV-3 recovered","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"DENV-4 recovered","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Total Viremia recovered","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Seropositive Study Participants Among Dengue Experienced and Dengue Naive Vaccinees.","description":"Measured by serum plaque reduction neutralization titer, 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses at study day 14, 28, 56, and 180 post vaccination. Seropositivity to each serotype is defined as PRNT50 ≥ 10.","populationDescription":"Only TV005 Vaccine arm included in analysis as per protocol to determine percentage of participants in TV005 vaccine arm who are seropositive after vaccination. Data is analyzed by sub-groups based on previous exposure to Dengue at baseline (experienced, and naïve). Two participants from the experienced at baseline group were eliminated from this analysis. There are 61 participants in the experienced at baseline group; 81 in the naïve at baseline group; total of 142 included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Study day 14 through study day 180","groups":[{"id":"OG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"classes":[{"title":"Experienced at baseline serpositive to DENV-1 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"94","upperLimit":"100"}]}]},{"title":"Experienced at baseline seropositive to DENV-2 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"94","upperLimit":"100"}]}]},{"title":"Experienced at baseline seropositive to DENV-3 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"94","upperLimit":"100"}]}]},{"title":"Experienced at baseline seropoisitive to DENV-4 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87","lowerLimit":"76","upperLimit":"93"}]}]},{"title":"Naive at baseline seropositive to DENV-1 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70","lowerLimit":"60","upperLimit":"79"}]}]},{"title":"Naive at baseline seropositive to DENV-2 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"93","upperLimit":"100"}]}]},{"title":"Naive at baseline seropositive to DENV-3 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"86","upperLimit":"97"}]}]},{"title":"Naive at baseline seropositive to DENV-4 post TV005 vaccination","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88","lowerLimit":"79","upperLimit":"93"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"DENV-1 percent seropositive post TV005 vaccination: difference between experienced at baseline and naive at baseline","nonInferiorityType":"SUPERIORITY","pValue":"<0.001","pValueComment":"Comparison between experienced vs dengue naive volunteers post TV005 vaccination. Logistic model to adjust for age cohort provides unstable estimates due to quasi separation of data.","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000"],"groupDescription":"DENV-2 percent seropositive post TV005 vaccination: difference between experienced at baseline and naive at baseline","nonInferiorityType":"SUPERIORITY","pValue":"1.00","pValueComment":"Comparison between experienced vs. dengue naive volunteers post TV005 vaccination. Logistic model to adjust for age cohort provides unstable estimates due to quasi separation of data.","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000"],"groupDescription":"DENV-3 percent seropositive post TV005 vaccination: difference between experienced at baseline and naive at baseline","nonInferiorityType":"SUPERIORITY","pValue":"0.070","pValueComment":"Comparison between experienced vs. dengue naive volunteers post TV005 vaccination. Logistic model to adjust for age cohort provides unstable estimates due to quasi separation of data.","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000"],"groupDescription":"DENV-4 percent seropositive post TV005 vaccination: difference between experienced at baseline and naive at baseline","nonInferiorityType":"SUPERIORITY","pValue":"1.00","pValueComment":"Comparison between experienced vs. dengue naive volunteers post TV005 vaccination. logistic model to adjust for age cohort provides unstable estimates due to quasi separation of data.","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Durability of Seropositivity Post TV005 Vaccination","description":"Estimated percent seropositive, over 3 years by age group and serotype. Measured by serum plaque reduction neutralization titer, 50% (PRNT50) to DENV-1, DENV-2, DENV-3, and DENV-4 viruses at study day 14, 28, 56, 180, 360, 720, and 1080 post vaccination. Seropositivity to each serotype is defined as PRNT50 ≥ 10.","populationDescription":"Only TV005 Vaccine arm included in analysis as per protocol to determine percentage of participants in TV005 vaccine arm who are seropositive after vaccination. Data is analyzed for each sub-group. Two participants (one each in Adult and Adolescent vaccine group) were eliminated from this analysis. There are 35 participants in Adult and Adolescent vaccine Arm groups; 36 in Children, and Young Children vaccine Arm groups with a total of 142 included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Vaccine/placebo administration (study day 0) up to three years post vaccine/placebo administration (study day 1080).","groups":[{"id":"OG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"}]}],"classes":[{"title":"Adult cohort: percent seropositive to DENV-1 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66","lowerLimit":"49","upperLimit":"79"}]}]},{"title":"Adult cohort: percent seropositive to DENV-1 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"67","upperLimit":"92"}]}]},{"title":"Adult cohort: percent seropositive to DENV-1 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80","lowerLimit":"64","upperLimit":"90"}]}]},{"title":"Adult cohort: percent seropositive to DENV-1 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80","lowerLimit":"64","upperLimit":"90"}]}]},{"title":"Adult cohort: percent seropositive to DENV-1 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80","lowerLimit":"64","upperLimit":"90"}]}]},{"title":"Adult cohort: percent seropositive to DENV-1 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66","lowerLimit":"49","upperLimit":"79"}]}]},{"title":"Adult cohort: percent seropositive to DENV-1 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66","lowerLimit":"49","upperLimit":"79"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69","lowerLimit":"52","upperLimit":"81"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"81","upperLimit":"98"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"74","upperLimit":"95"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"74","upperLimit":"95"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Adult cohort: percent seropositive to DENV-2 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71","lowerLimit":"55","upperLimit":"84"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"81","upperLimit":"98"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"74","upperLimit":"95"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"74","upperLimit":"95"}]}]},{"title":"Adult cohort: percent seropositive to DENV-3 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80","lowerLimit":"64","upperLimit":"90"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20","lowerLimit":"10","upperLimit":"36"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77","lowerLimit":"61","upperLimit":"88"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80","lowerLimit":"64","upperLimit":"90"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74","lowerLimit":"58","upperLimit":"86"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66","lowerLimit":"49","upperLimit":"79"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60","lowerLimit":"44","upperLimit":"74"}]}]},{"title":"Adult cohort: percent seropositive to DENV-4 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63","lowerLimit":"46","upperLimit":"77"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26","lowerLimit":"14","upperLimit":"42"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74","lowerLimit":"58","upperLimit":"86"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71","lowerLimit":"55","upperLimit":"84"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71","lowerLimit":"55","upperLimit":"84"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69","lowerLimit":"52","upperLimit":"81"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43","lowerLimit":"28","upperLimit":"59"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-1 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46","lowerLimit":"30","upperLimit":"62"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34","lowerLimit":"21","upperLimit":"51"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"90","upperLimit":"100"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74","lowerLimit":"58","upperLimit":"86"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-2 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69","lowerLimit":"52","upperLimit":"81"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37","lowerLimit":"23","upperLimit":"54"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"74","upperLimit":"95"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"81","upperLimit":"98"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"85","upperLimit":"99"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"74","upperLimit":"95"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57","lowerLimit":"41","upperLimit":"72"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-3 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57","lowerLimit":"41","upperLimit":"72"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"10"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"67","upperLimit":"92"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77","lowerLimit":"61","upperLimit":"88"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71","lowerLimit":"55","upperLimit":"84"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66","lowerLimit":"49","upperLimit":"79"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60","lowerLimit":"44","upperLimit":"74"}]}]},{"title":"Adolescent cohort: percent seropositive to DENV-4 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43","lowerLimit":"28","upperLimit":"59"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31","lowerLimit":"18","upperLimit":"47"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69","lowerLimit":"53","upperLimit":"82"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61","lowerLimit":"45","upperLimit":"75"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56","lowerLimit":"40","upperLimit":"70"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42","lowerLimit":"27","upperLimit":"58"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42","lowerLimit":"27","upperLimit":"58"}]}]},{"title":"Children cohort: percent seropositive to DENV-1 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36","lowerLimit":"22","upperLimit":"54"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33","lowerLimit":"20","upperLimit":"50"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"75","upperLimit":"96"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78","lowerLimit":"62","upperLimit":"88"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67","lowerLimit":"50","upperLimit":"80"}]}]},{"title":"Children cohort: percent seropositive to DENV-2 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58","lowerLimit":"42","upperLimit":"73"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36","lowerLimit":"22","upperLimit":"52"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92","lowerLimit":"78","upperLimit":"97"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"86","upperLimit":"100"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72","lowerLimit":"56","upperLimit":"84"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72","lowerLimit":"56","upperLimit":"84"}]}]},{"title":"Children cohort: percent seropositive to DENV-3 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67","lowerLimit":"50","upperLimit":"80"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11","lowerLimit":"4","upperLimit":"25"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72","lowerLimit":"56","upperLimit":"84"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56","lowerLimit":"40","upperLimit":"70"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44","lowerLimit":"30","upperLimit":"60"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28","lowerLimit":"16","upperLimit":"44"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25","lowerLimit":"14","upperLimit":"41"}]}]},{"title":"Children cohort: percent seropositive to DENV-4 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19","lowerLimit":"10","upperLimit":"35"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11","lowerLimit":"4","upperLimit":"25"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78","lowerLimit":"62","upperLimit":"88"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42","lowerLimit":"27","upperLimit":"58"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53","lowerLimit":"37","upperLimit":"68"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28","lowerLimit":"16","upperLimit":"44"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28","lowerLimit":"16","upperLimit":"44"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-1 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28","lowerLimit":"16","upperLimit":"44"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11","lowerLimit":"4","upperLimit":"25"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97","lowerLimit":"86","upperLimit":"100"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81","lowerLimit":"65","upperLimit":"90"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83","lowerLimit":"68","upperLimit":"92"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72","lowerLimit":"56","upperLimit":"84"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-2 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69","lowerLimit":"53","upperLimit":"82"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8","lowerLimit":"3","upperLimit":"22"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"71","upperLimit":"94"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67","lowerLimit":"50","upperLimit":"80"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"34","upperLimit":"66"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25","lowerLimit":"14","upperLimit":"41"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31","lowerLimit":"18","upperLimit":"47"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-3 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25","lowerLimit":"14","upperLimit":"41"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3","lowerLimit":"0","upperLimit":"14"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89","lowerLimit":"75","upperLimit":"96"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72","lowerLimit":"56","upperLimit":"96"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 180","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47","lowerLimit":"32","upperLimit":"63"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 360","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28","lowerLimit":"16","upperLimit":"44"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 720","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28","lowerLimit":"16","upperLimit":"44"}]}]},{"title":"Young Children cohort: percent seropositive to DENV-4 at study day 1080","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22","lowerLimit":"12","upperLimit":"38"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49","ciUpperLimit":"79"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"67","ciUpperLimit":"92"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"64","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"64","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"64","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49","ciUpperLimit":"79"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-1 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49","ciUpperLimit":"79"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"52","ciUpperLimit":"81"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at stud day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"81","ciUpperLimit":"98"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at study day 180. There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"95"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"95"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-2 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"81","ciUpperLimit":"98"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"95"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"95"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-3 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"64","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"20","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"10","ciUpperLimit":"36"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"61","ciUpperLimit":"88"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"64","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"58","ciUpperLimit":"86"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49","ciUpperLimit":"79"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"44","ciUpperLimit":"74"},{"groupIds":["OG000"],"groupDescription":"Adult cohort: percent seropositive to DENV-4 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"46","ciUpperLimit":"77"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 a study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14","ciUpperLimit":"42"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"58","ciUpperLimit":"86"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"52","ciUpperLimit":"81"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"28","ciUpperLimit":"59"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-1 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"30","ciUpperLimit":"62"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"21","ciUpperLimit":"51"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"100","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"90","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"58","ciUpperLimit":"86"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-2 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"52","ciUpperLimit":"81"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"37","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"23","ciUpperLimit":"54"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"95"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"81","ciUpperLimit":"98"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"85","ciUpperLimit":"99"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"95"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"41","ciUpperLimit":"72"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-3 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"41","ciUpperLimit":"72"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0","ciUpperLimit":"10"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"67","ciUpperLimit":"92"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"61","ciUpperLimit":"88"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"49","ciUpperLimit":"79"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"44","ciUpperLimit":"74"},{"groupIds":["OG000"],"groupDescription":"Adolescent cohort: percent seropositive to DENV-4 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"28","ciUpperLimit":"59"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"18","ciUpperLimit":"47"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"53","ciUpperLimit":"82"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"45","ciUpperLimit":"75"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"40","ciUpperLimit":"70"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27","ciUpperLimit":"58"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27","ciUpperLimit":"58"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-1 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"22","ciUpperLimit":"54"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-2 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"20","ciUpperLimit":"50"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-2 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-2 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"75","ciUpperLimit":"96"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-2 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"children cohort: percent seropositive to DENV-2 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62","ciUpperLimit":"88"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-2 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"50","ciUpperLimit":"80"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-2 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"42","ciUpperLimit":"73"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"22","ciUpperLimit":"52"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"97"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"86","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-3 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"50","ciUpperLimit":"80"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-4 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4","ciUpperLimit":"25"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-4 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-4 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"40","ciUpperLimit":"70"},{"groupIds":["OG000"],"groupDescription":"children cohort: percent seropositive to DENV-4 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"30","ciUpperLimit":"60"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-4 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16","ciUpperLimit":"44"},{"groupIds":["OG000"],"groupDescription":"Children cohort: percent seropositive to DENV-4 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14","ciUpperLimit":"41"},{"groupIds":["OG000"],"groupDescription":"children cohort: percent seropositive to DENV-4 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"10","ciUpperLimit":"35"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-1 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4","ciUpperLimit":"25"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-1 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62","ciUpperLimit":"88"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-1 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27","ciUpperLimit":"58"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-1 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"37","ciUpperLimit":"68"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-1 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16","ciUpperLimit":"44"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-1 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16","ciUpperLimit":"44"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-1 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16","ciUpperLimit":"44"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-2 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4","ciUpperLimit":"25"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-2 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"86","ciUpperLimit":"100"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-2 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-2 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"65","ciUpperLimit":"90"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-2 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"83","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68","ciUpperLimit":"92"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-2 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"Slope","paramValue":"72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56","ciUpperLimit":"84"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-2 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"53","ciUpperLimit":"82"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-3 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3","ciUpperLimit":"22"},{"groupIds":["OG000"],"groupDescription":"Young children cohort: percent seropositive to DENV-3 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-3 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"50","ciUpperLimit":"80"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-3 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"34","ciUpperLimit":"66"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-3 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14","ciUpperLimit":"41"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-3 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"18","ciUpperLimit":"47"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-3 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"14","ciUpperLimit":"41"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 0 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0","ciUpperLimit":"14"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 28 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"75","ciUpperLimit":"96"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 56 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56","ciUpperLimit":"96"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 180 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"32","ciUpperLimit":"63"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 360 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16","ciUpperLimit":"44"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 720 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"16","ciUpperLimit":"44"},{"groupIds":["OG000"],"groupDescription":"young children cohort: percent seropositive to DENV-4 at study day 1080 There is no comparison between arms. Only the percentage seropositive in the TV005 vaccine arm is being estimated with confidence interval.","nonInferiorityType":"OTHER","nonInferiorityComment":"Estimate of the percentage in each sub-group in the TV005 vaccine arm.","paramType":"percentage seropositive","paramValue":"22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"12","ciUpperLimit":"38"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"All-cause mortality and SAEs were assessed through three years post-vaccination; solicited and all other adverse events were assessed through 28 days post vaccination","description":"Time frame for solicited adverse events is up to 28 days post vaccination; time frame for SAE and all-cause mortality is three years post vaccination","eventGroups":[{"id":"EG000","title":"TV005 Vaccine","description":"Participants will receive one dose of TV005 vaccine at study entry (Day 0).\n\nTV005 vaccine: Delivered by subcutaneous injection; contains 10\\^3 PFU of rDEN1Δ30, 10\\^4 PFU of rDEN2/4Δ30(ME), 10\\^3 PFU of rDEN3Δ30/31, and 10\\^3 PFU of rDEN4Δ30.","deathsNumAffected":0,"deathsNumAtRisk":144,"seriousNumAffected":6,"seriousNumAtRisk":144,"otherNumAffected":95,"otherNumAtRisk":144},{"id":"EG001","title":"Placebo","description":"Participants will receive one dose of placebo at study entry (Day 0).\n\nPlacebo: Delivered by subcutaneous injection","deathsNumAffected":0,"deathsNumAtRisk":48,"seriousNumAffected":0,"seriousNumAtRisk":48,"otherNumAffected":25,"otherNumAtRisk":48}],"seriousEvents":[{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Appendicitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"ALT Increase","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Endocarditis Infective","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Typhoid Fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]}],"otherEvents":[{"term":"Injection site erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":144},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":48}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":48}]},{"term":"Headache","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":144},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":48}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":37,"numAtRisk":144},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":48}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":144},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":48}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"ALT Elevated","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":144},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":48}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":48}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Retro-orbital pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":48}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":144},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":48}]},{"term":"Photophobia","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Hemoglobin decreasaed","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":144},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":48}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":48}]},{"term":"PT Prolonged","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"PTT prolonged","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":144},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":48}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Decreased appetite","organSystem":"General disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (18.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":48}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Beth Kirkpatrick MD","organization":"University of Vermont","email":"beth.kirkpatrick@med.uvm.edu","phone":"802-656-5822"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2017-06-16","uploadDate":"2024-02-20T12:11","filename":"Prot_SAP_001.pdf","size":889142},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2016-07-27","uploadDate":"2024-02-20T11:20","filename":"ICF_002.pdf","size":351475}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003715","term":"Dengue"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}]}},"hasResults":true}